# Ebola in Congo, the Clinical Trial That Could Change Everything

> Introduction: one first patient, one cautious hope

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Editorial
- Published: 2026-07-04
- Canonical URL: https://mad-max.co/en/article/ebola-au-congo-lessai-clinique-qui-pourrait-tout-changer

## Key takeaways

- The WHO confirmed on July 2, 2026 that the first patient had been enrolled; the DRC had 1,460 confirmed cases and 452 deaths, most in Ituri province.
- The randomized platform trial has four arms: MBP134 alone, remdesivir alone, both combined, and supportive care as the control.
- The trial is coordinated by DRC's INRB, Belgium's Institute of Tropical Medicine, and the University of Oxford, with WHO support, and may need up to a thousand patients, possibly running into 2027.
- Drug donations came from the United States (MBP134) and Gilead Sciences (remdesivir), and the WHO is discussing post-trial access.
- The WHO listed the first diagnostic test for this strain, and contact tracing remains difficult due to insecurity; Africa CDC flagged a $21.5 million funding gap.

## Introduction: one first patient, one cautious hope

### A quiet announcement with heavy implications

On **July 2, 2026**, the **World Health Organization** confirmed that a **first patient** had just been enrolled in a **clinical trial** designed to test two potential treatments against the **Bundibugyo** strain of the **Ebola** virus, behind an **outbreak** that has been hitting eastern **Democratic Republic of Congo** since May. This moment, described by WHO Director-General **Tedros Adhanom Ghebreyesus** as a decisive milestone, is no media stunt: it is the result of weeks of scientific and logistical preparation.

To understand why this launch matters, one first has to grasp the scale of the situation on the ground. According to data published by the **European Centre for Disease Prevention and Control**, the **DRC** had, as of **July 2, 2026**, a total of **1,460 confirmed cases** and **452 deaths** linked to this outbreak, with **213 people** having recovered. These numbers are a cold clinical reminder that every week without an approved treatment costs lives.

### Why this strain defeats existing tools

The **Bundibugyo** strain is less familiar to the public than the **Zaire** strain, responsible for the massive West African outbreaks of 2014 and the one in eastern Congo in 2018–2020. Yet it poses a very concrete problem: no **approved vaccine** and no **approved treatment** currently exists against it, unlike the Zaire strain, for which the **Ervebo** vaccine and certain monoclonal antibodies have already proven effective.

This is precisely the gap the trial launched this week is trying to close. *In a world saturated with bad health news, I find it reassuring to see the scientific community respond this quickly to a strain we were nearly starting from zero on.*

## What the clinical trial will actually test

### Two compounds, four patient groups

According to reporting by **Reuters** and confirmed by the University of Minnesota's **Center for Infectious Disease Research and Policy**, the trial is a **randomized platform trial** that will evaluate the **MBP134 monoclonal antibody**, developed by **Mapp Biopharmaceutical**, alongside **remdesivir**, the **Gilead Sciences** antiviral already familiar to the public from its use against COVID-19.

In practice, patients will be split into **four groups**: one group will receive only **MBP134**, a second only **remdesivir**, a third will receive the **combination of both**, and a control group will receive the **best available supportive care**. Other treatments could be added over time if new scientific data justify it.

### An international scientific partnership

The trial is coordinated by the DRC's **National Institute for Biomedical Research**, Belgium's **Institute of Tropical Medicine**, and the **University of Oxford**, with support from the **WHO**. This collaboration between Congolese, Belgian, and British researchers illustrates a dimension often forgotten in major health emergencies: the most effective response rarely comes from a single country acting alone.

According to **Dr. Vasee Moorthy**, acting head of WHO's **R&D Blueprint** group, this trial may need to enroll **up to a thousand patients** before yielding a definitive answer, a process that could stretch over several months, potentially into 2027. *This honesty about the timeline strikes me as just as important as the trial itself: no one is promising a miracle in a few weeks, and that is exactly the tone needed when facing a disease this deadly.*

## The real scale of the outbreak on the ground

### Ituri, the epicenter of a humanitarian crisis

The province of **Ituri**, in northeastern **DRC**, accounts for most of the virus's spread. According to the **ECDC**, it alone had **1,333 confirmed cases** and **380 deaths**, spread across **24 of the province's 36 health zones**. The neighboring province of **North Kivu** reported **124 cases** and **71 deaths**, while **South Kivu** remained relatively spared with just **three cases**.

These figures tell only part of the story. The **WHO** itself describes the area as "**densely populated**" and marked by **chronic insecurity**, two factors that considerably complicate the work of contact-tracing and vaccination teams.

### A health system under extreme strain

According to **Reuters**, capacity at Ebola treatment centers had already reached **650 beds**, about **96% occupied** at the time the trial launched. The **WHO** is actively working to add **300 more beds** to meet rising demand, a considerable logistical effort in a region where road and medical infrastructure remain fragile.

The **fatality** rate observed in some areas, notably **North Kivu** where it reached **56.7%** according to earlier CIDRAP data, is a reminder of how much every single day matters for care teams. *These ground-level numbers, more than any official statement, show the real urgency behind this trial's launch.*

## The critical role of drug donations

### Gilead and the United States open their reserves

Releasing drugs for this trial was never automatic. According to **Reuters**, the **United States** donated part of its **MBP134** reserves, while **Gilead Sciences** announced it had supplied more than **2,000 additional vials** of **remdesivir** for the clinical trial, on top of the **2,000 vials** already donated in **June** for emergency compassionate use.

The **WHO** stated it is in discussions with both partners to ensure patients in the **DRC** can keep accessing these treatments after the trial, should they prove safe and effective. This is a point often overlooked in media coverage of this kind of announcement, yet it determines whether the research actually benefits the affected populations.

### A lesson learned from previous crises

This push to secure post-trial access stems directly from criticism faced during earlier Ebola outbreaks, when promising treatments sometimes remained out of reach for local populations once clinical trials ended. Several organizations, including **Public Citizen** and **AVAC**, had publicly called as early as June for **MBP134** to be made available more quickly. *Seeing these lessons from the past concretely shape how treatment access is negotiated today strikes me as one of the rare tangible improvements in global health governance.*

## What these two compounds really represent

### MBP134, an antibody born from a past epidemic

**MBP134** is not a drug invented overnight. This monoclonal antibody cocktail was developed from antibodies taken from survivors of the 2014 West African outbreak, then initially engineered to target the **Sudan** strain of the virus with support from the U.S. agency **BARDA**. Its pan-ebolavirus potential — its ability to act against multiple strains of the virus — makes it a candidate researchers are watching closely.

This kind of reuse of earlier research illustrates a reality little known to the public: scientific advances made against one epidemic often become the foundation for responses to the next, even when the viral strain differs.

### Remdesivir, between its COVID legacy and a new use

**Remdesivir**, for its part, is mostly known to the public for its use during the **COVID-19** pandemic. According to **CIDRAP**, it had already shown **in vitro activity** against the Bundibugyo strain and had been used in earlier trials against the Zaire strain, notably as part of the **PALM** study. Neither drug, however, has yet been tested in humans specifically for treating Bundibugyo-type Ebola, which makes this trial all the more scientifically significant.

This absence of prior human data explains why the **WHO** is emphasizing methodological caution rather than hasty promises. *I clearly prefer this rigorous approach over spectacular announcements that, historically, have often let down the populations most vulnerable to Ebola.*

## Testing: a link too often overlooked

### A new test added to WHO's emergency list

The same day the clinical trial began, the **WHO** added the **first diagnostic test** for Bundibugyo Ebola virus to its **emergency use listing**, an essential regulatory step that speeds up the test's rollout in affected areas. Before this announcement, only one or two diagnostic tests were available for this specific strain, according to an emergency scientific consultation report published in late May.

This technical detail has very concrete consequences on the ground: the faster and more reliable the tests, the sooner infected patients can be isolated and treated, reducing the chances of transmission to those around them.

### Contact tracing, an immense human challenge

According to **ECDC** data, roughly **82.7% of identified contacts** remained under active monitoring in the Ituri and North Kivu provinces as of early July. That figure, while encouraging, hides a more complex reality: in certain areas, contact-tracing coverage was still described as "**suboptimal**" by the WHO itself, largely due to insecurity and the high mobility of local populations.

These operational difficulties are a reminder that medical technology, however promising, is never enough on its own to stop an outbreak of this scale. *This may be the most important lesson of this crisis: a brilliant clinical trial is worth nothing without field teams capable of tracking every contact, every suspected case, every isolated village.*

## A spread that has already crossed borders

### Cases exported to Europe and North America

The reach of this outbreak is no longer confined to Central Africa. According to the **ECDC**, an imported case was reported in **France** on **June 24, 2026** by the health ministry, while an American citizen was medically evacuated to **Germany** for treatment. Both cases originated directly from the areas affected by the ongoing outbreak in the DRC.

Despite these exported cases, the **ECDC** maintains that the risk to populations in the **European Union** remains "**very low**," an assessment that will be revised if new data change the picture.

### Uganda: a situation that appears to be stabilizing

In **Uganda**, the situation looks considerably more under control. According to the most recent data, the country had **20 confirmed cases** and **two deaths**, with no new cases reported since **June 21**. Of the recorded cases, **fifteen** had a direct travel link to the DRC, and **fifteen people** in total had recovered.

This relative stabilization in Uganda stands in contrast to the still-rising trajectory seen on the Congolese side, where new health zones continue to be affected. *I find this comparison between the two countries telling: it shows that a fast, well-coordinated response can genuinely slow the spread, even against a strain this poorly understood.*

## Funding, a blind spot too often forgotten

### A funding shortfall documented from the earliest weeks

One month after the World Health Organization officially recognized the outbreak, **Africa CDC** was already publicly warning of a **$21.5 million funding gap**, deemed critical to sustaining contact-tracing efforts and medical supply chains. This kind of budget warning, far less dramatic than a clinical trial announcement, nonetheless determines very concretely whether field teams can contain the spread.

**Africa CDC** summed up the situation bluntly on social media, noting that the outbreak was "not yet under control" and that critical gaps remained in contact tracing and basic medical supplies.

### An international mobilization that remains fragile

While drug donations like those from **Gilead Sciences** have grabbed media attention, funding for the day-to-day operations on the ground, often far less visible, remains just as decisive. Without trained staff, without fuel for tracing teams, without sufficient isolation capacity, even the most promising treatment cannot reach the patients who need it in time.

This budgetary reality is a reminder that responding to an outbreak rests on a fragile balance between scientific innovation and field logistics, two dimensions that must advance together to produce a real impact on the number of lives saved.

*We talk a lot about the compounds and the laboratories, but rarely about that missing twenty-some million dollars on the ground; yet that is often exactly where the line falls between a contained outbreak and an uncontrolled spread.*

## Conclusion: measured hope, not an announced miracle

### What this trial can actually change

The launch of this clinical trial does not mean the outbreak is nearing its end, nor that the **452 deaths** already recorded will be the last. It does, however, represent a concrete scientific milestone after months during which medical teams on the ground had to make do with supportive care, with no targeted treatment against the Bundibugyo strain.

If the trial's results confirm the effectiveness of **MBP134**, **remdesivir**, or their combination, it will be the first time the medical community has a validated therapeutic tool specifically against this strain, with potential implications reaching well beyond the current outbreak alone.

### Why caution is still warranted

The road ahead remains long. A trial that may need up to a thousand patients and could run for several months means definitive answers will not arrive before the current outbreak, one way or another, reaches its own conclusion. That is a difficult reality to accept, but it deserves to be stated plainly rather than dressed up as a premature victory.

What I choose to take from this week is a signal of measured hope: an international scientific community mobilized, concrete drug donations, and Congolese researchers at the heart of the effort rather than relegated to mere observers.

*This is real progress, but fragile progress, one that will depend as much on scientific rigor as on the world's willingness not to look away before the trial delivers its results.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- [World Health Organization — Ebola outbreak - DRC 2026 — July 2, 2026](https://www.who.int/emergencies/situations/ebola-outbreak---drc-2026)

- [Reuters — Trial for Bundibugyo Ebola treatment starts in DRC, WHO says — July 2, 2026](https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/)

- [European Centre for Disease Prevention and Control — Ebola disease outbreak in the DRC and Uganda — July 3, 2026](https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda)

### Secondary sources

- [CIDRAP — Clinical trial for Ebola therapies begins in DR Congo — July 2, 2026](https://www.cidrap.umn.edu/ebola/clinical-trial-ebola-therapies-begins-dr-congo)

- [BBC — Ebola treatments trial begins in the Democratic Republic of Congo — July 3, 2026](https://www.bbc.com/news/articles/c75ykve4zzxo)

- [CIDRAP — Experts urge use of experimental antibodies in DR Congo to combat Ebola — June 17, 2026](https://www.cidrap.umn.edu/ebola/experts-urge-use-experimental-antibodies-dr-congo-combat-ebola)

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/ebola-au-congo-lessai-clinique-qui-pourrait-tout-changer